…
Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, beverages, gummies, and concentrates; and adult use recreational cannabis under the SHRED, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Boxhot, Edison JOLTS, Wola, Rizzlers, DEBUNK, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings and dried flowers to other licensed producers. It sells cannabis products to wholesale and retail channels in the recreational and medical cannabis regimes, as well as through online. Organigram Global Inc. was formerly known as Organigram Holdings Inc. and changed its name to Organigram Global Inc. in March 2025. The company is headquartered in Toronto, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
OrganiGram Holdings Inc is a Canadian licensed cannabis producer that cultivates, processes and sells adult-use and medical cannabis across dried flower, extracts and other derivative formats. Long-term growth could be supported by expansion of Canada's recreational market, product innovation in value-added formats, capacity improvements and selective international opportunities; investors may find the company attractive for its focused product portfolio and potential to benefit from industry consolidation.
Principal risks include regulatory and policy uncertainty, intense domestic competition and pricing pressure, execution and supply-chain challenges, and exposure to financing and market cycles that could constrain growth.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2022-08-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2022-08-31 |
| Income before tax | -27.66M | -45.44M | -233.00M | -14.37M | -14.37M |
| Net income | -17.78M | -45.44M | -229.48M | -14.28M | -14.28M |
| Selling general administrative | 55.78M | 47.38M | 53.82M | 42.35M | 42.35M |
| Selling and marketing expenses | 31.10M | 19.85M | 17.86M | 16.86M | 16.86M |
| Gross profit | 6.83M | 47.52M | 35.07M | 31.57M | 31.57M |
| Reconciled depreciation | 17.98M | 12.08M | - | 24.91M | 24.91M |
| Ebit | -27.66M | -34.76M | -48.79M | -13.94M | -38.75M |
| Ebitda | -14.76M | -22.68M | -25.37M | 10.96M | -15.21M |
| Depreciation and amortization | 12.91M | 12.08M | 23.42M | 24.91M | 23.54M |
| Operating income | -63.41M | -34.76M | -242.74M | -38.75M | -38.75M |
| Other operating expenses | 249.50M | 194.60M | 391.94M | 184.56M | 184.56M |
| Interest expense | - | - | 0.28M | 0.43M | 0.43M |
| Tax provision | -13.77M | 0.00M | - | -0.09M | -0.09M |
| Net interest income | - | - | - | -0.43M | -0.43M |
| Income tax expense | -9.89M | - | -3.52M | -0.09M | -0.09M |
| Total revenue | 186.09M | 159.84M | 149.21M | 145.81M | 145.81M |
| Total operating expenses | 70.24M | 82.28M | 277.81M | 70.32M | 70.32M |
| Cost of revenue | 179.26M | 112.32M | 114.13M | 114.24M | 114.24M |
| Total other income expense net | 35.74M | -10.68M | 9.74M | 24.38M | 24.38M |
| Net income from continuing ops | -24.76M | -45.44M | - | -14.28M | -14.28M |
| Net income applicable to common shares | - | - | -229.48M | -14.28M | -14.28M |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2023-08-31 | 2022-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2023-08-31 | 2022-09-30 |
| Total assets | 562.21M | 407.86M | 298.45M | 298.45M | 577.11M |
| Intangible assets | 48.51M | 8.09M | 10.62M | 10.62M | 14.26M |
| Other current assets | 67.06M | 34.98M | 13.70M | 11.00M | 8.36M |
| Total liab | 213.08M | 101.87M | 26.83M | 26.83M | 69.05M |
| Total stockholder equity | 349.13M | 305.99M | 271.62M | 271.62M | 508.06M |
| Deferred long term liab | - | - | 0.39M | 0.39M | 0.03M |
| Other current liab | 35.91M | 5.14M | 1.33M | 1.24M | 12.00M |
| Common stock | 919.91M | 852.89M | 776.91M | 776.91M | 769.73M |
| Capital stock | 919.91M | 852.89M | - | - | 769.73M |
| Retained earnings | -608.73M | -583.97M | -538.53M | -538.53M | -289.93M |
| Other liab | - | - | 0.77M | 0.77M | 11.40M |
| Good will | 52.52M | 0.00M | - | - | 41.98M |
| Other assets | - | - | 0.00M | 0.00M | 33.14M |
| Cash | 28.20M | 106.75M | 33.86M | 33.86M | 68.52M |
| Total current liabilities | 126.16M | 53.32M | 22.43M | 22.43M | 55.28M |
| Current deferred revenue | - | - | 0.09M | 0.09M | 2.44M |
| Net debt | -19.45M | -102.29M | -29.14M | -29.14M | -65.16M |
| Short term debt | 1.00M | 1.09M | 1.09M | 1.09M | 1.00M |
| Short long term debt | 0.03M | 0.06M | - | - | 0.08M |
| Short long term debt total | 8.75M | 4.46M | 4.72M | 4.72M | 3.36M |
| Other stockholder equity | - | - | 33.24M | 33.24M | 28.26M |
| Property plant equipment | - | - | 99.05M | 99.05M | 259.82M |
| Total current assets | 284.90M | 262.22M | 155.98M | 155.98M | 221.62M |
| Long term investments | 49.55M | 40.77M | - | - | 7.07M |
| Net tangible assets | - | - | 261.00M | 261.00M | 451.82M |
| Short term investments | 0.83M | 0.82M | - | - | 30.09M |
| Net receivables | 64.86M | 37.15M | 27.46M | 30.16M | 46.37M |
| Long term debt | - | 0.03M | - | - | 0.15M |
| Inventory | 123.95M | 82.52M | 80.95M | 80.95M | 68.28M |
| Accounts payable | 89.25M | 47.10M | 20.01M | 20.01M | 40.86M |
| Accumulated other comprehensive income | 37.95M | 37.07M | 33.24M | 33.24M | 28.26M |
| Non currrent assets other | 3.75M | 0.59M | 19.09M | 0.61M | 33.14M |
| Non current assets total | 277.31M | 145.64M | 142.48M | 142.48M | 355.48M |
| Capital lease obligations | 8.73M | 4.37M | - | - | 3.12M |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2022-08-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2022-08-31 |
| Investments | 1.49M | -38.77M | 20.15M | 95.47M | 95.47M |
| Change to liabilities | - | - | -17.60M | 12.15M | 12.15M |
| Total cashflows from investing activities | -81.07M | -30.80M | 1.35M | 44.03M | 44.03M |
| Net borrowings | -1.85M | -0.79M | -0.77M | -1.01M | -1.01M |
| Total cash from financing activities | 39.33M | 107.78M | -0.81M | 5.33M | 5.33M |
| Change to operating activities | - | - | - | 1.21M | 1.21M |
| Net income | -24.76M | -45.44M | -229.48M | -14.28M | -14.28M |
| Change in cash | -49.01M | 80.85M | -36.87M | 13.15M | 13.15M |
| Begin period cash flow | 132.60M | 51.76M | 70.62M | 55.37M | 55.37M |
| End period cash flow | 83.59M | 132.60M | 33.86M | 68.52M | 68.52M |
| Total cash from operating activities | -7.59M | 3.87M | -35.08M | -36.21M | -36.21M |
| Issuance of capital stock | 41.18M | 108.56M | - | 0.00M | 0.00M |
| Depreciation | 17.98M | 12.08M | 24.17M | 24.91M | 24.91M |
| Other cashflows from investing activities | 0.09M | -0.35M | 28.25M | 5.75M | 5.78M |
| Dividends paid | - | - | - | 0.00M | 0.00M |
| Change to inventory | - | - | - | -12.22M | -12.22M |
| Change to account receivables | -15.29M | -12.06M | 12.51M | -37.66M | -24.02M |
| Other cashflows from financing activities | -1.29M | 0.01M | -0.75M | -0.09M | 6.34M |
| Change to netincome | - | - | 174.60M | -23.96M | -23.96M |
| Capital expenditures | 17.05M | 5.34M | 26.90M | 48.78M | 48.78M |
| Change in working capital | -2.12M | 14.96M | 12.51M | -22.88M | -22.88M |
| Stock based compensation | 4.22M | 7.18M | 5.29M | 5.13M | 5.13M |
| Other non cash items | 10.87M | 15.09M | 152.43M | -29.00M | -29.00M |
| Free cash flow | -24.64M | -1.47M | -61.98M | -84.99M | -84.99M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| OGI OrganiGram Holdings Inc |
-0.05 5.72% |
0.88 | 2.52 | 14.97 | 0.49 | 0.45 | 0.76 | 12.75 |
| MKKGY Merck KGaA ADR |
-0.22 0.66% |
33.17 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
-2.76 1.62% |
167.12 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
-0.17 0.80% |
21.02 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
41.85 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, beverages, gummies, and concentrates; and adult use recreational cannabis under the SHRED, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Boxhot, Edison JOLTS, Wola, Rizzlers, DEBUNK, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings and dried flowers to other licensed producers. It sells cannabis products to wholesale and retail channels in the recreational and medical cannabis regimes, as well as through online. Organigram Global Inc. was formerly known as Organigram Holdings Inc. and changed its name to Organigram Global Inc. in March 2025. The company is headquartered in Toronto, Canada.
| Name | Title | Year Born |
|---|---|---|
| Ms. Nathalie Batten | VP of Operations | NA |
| Mr. Derrick W. West CPA, CPA, (CA) | Chief Financial Officer | 1967 |
| Ms. Helen Martin | Chief Legal Officer & Corp. Sec. | 1978 |
| Mr. Gregory Engel | Special Advisor | 1965 |
| Mr. Timothy Emberg | Chief Revenue Officer | NA |
| Mr. Paolo De Luca C.A., C.F.A | Chief Strategy Officer | 1973 |
| Ms. Beena G. Goldenberg | CEO & Director | 1963 |
| Mr. Geoff Riggs | Chief Information Officer | NA |
| Amy Schwalm | VP of Investor Relations | NA |
| Ms. Megan Amber McCrae | Sr. VP of Marketing & Communications | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.